Abstract:
Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient, wherein expression of Epo is physiologically regulated such that hematocrit levels of the patient are corrected and maintained.
Abstract:
Apparatus is described for storing sensitive materials in containers (32) which are sealed and in which the internal atmosphere may be purged by flushing with an inert gas fed in from a purger unit (30) via a suitable feed lead (35). The gas exhausted from inside the container (32) is fed back into the purge unit (30) and then checked against a desired parameter, for example oxygen concentration, until the value of that parameter reaches a desired level. Purging may then be stopped and the container left sealed, preferably at a slight over pressure relative to the ambient atmosphere. The use of a separate purge unit enables many containers to be sequentially and effectively processed. The containers are particularly useful for storing sensitive chemical and biological samples.
Abstract:
Disclosed and claimed are methods for treating or preventing neurodegenerative diseases, conditions or maladies or symptoms or physiology associated therewith, such as treating or preventing Parkinson's disease or symptoms or physiology associated therewith such as motor deficits or nigrostriatal degeneration; or, for inducing nigrostriatal regeneration. Advantageously, the methods involve administering a lentiviral vector that expresses GDNF, such as human GDNF, or a variant, homolog, analog or derivative thereof.
Abstract:
The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response to the antigen and a reduced immune response to the viral vector are indicative of an effective immunotherapy.
Abstract:
Apparatus for purging containers for the storage of sensitive materials is described. It includes means to connect a source of compressed purge gas to a purge gas inlet (2) on a container (1), including a pneumatically operated valve (6) adapted to allow purge gas to pass from the source to the inlet and a timing device (9) associated with the valve (6) and adapted to turn off the gas flow after a given time, and including means to vary the time between commencement and cessation of gas flow. The timing device is preferably one which operates on a pneumatic or clockwork basis, enabling the apparatus to operate without any electrical power supply, driven by the purge gas pressure alone. This enables the construction of a simple reliable unit, at a cost even enabling the unit to be incorporated into the container itself if desired. The use of a pneumatically operated valve enables portable apparatus to be designed with low power use if it includes e.g. electronic sensors to measure a property of the purge gas being exhausted from the container.
Abstract:
Apparatus for purging containers for the storage of sensitive materials is described. It includes means to connect a source of compressed purge gas to a purge gas inlet (2) on a container (1), including a pneumatically operated valve (6) adapted to allow purge gas to pass from the source to the inlet and a timing device (9) associated with the valve (6) and adapted to turn off the gas flow after a given time, and including means to vary the time between commencement and cessation of gas flow. The timing device is preferably one which operates on a pneumatic or clockwork basis, enabling the apparatus to operate without any electrical power supply, driven by the purge gas pressure alone. This enables the construction of a simple reliable unit, at a cost even enabling the unit to be incorporated into the container itself if desired. The use of a pneumatically operated valve enables portable apparatus to be designed with low power use if it includes e.g. electronic sensors to measure a property of the purge gas being exhausted from the container.
Abstract:
The present invention provides a method of monitoring the efficacy of an immunotherapy in a mammalian subject, wherein the subject has been administered an immunotherapy, wherein the immunotherapy comprises a viral vector containing a polynucleotide encoding an antigen, wherein the viral vector is capable of transducing cells in the mammalian subject to cause the cells to express the antigen; the method comprising: (b) measuring, from a biological sample isolated from the subject, an immune response of the subject to the antigen and comparing the immune response of the subject to the antigen to a reference measurement of immune response to the antigen; (c) measuring, from a biological sample isolated from the subject, an immune response of the subject to the viral vector and comparing the immune response of the subject to the viral vector to a reference measurement of immune response to the viral vector; and (d) determining efficacy based on the comparisons of (b) and (c), wherein an elevated immune response to the antigen and a reduced immune response to the viral vector are indicative of an effective immunotherapy.
Abstract:
Apparatus is described for storing sensitive materials in containers (32) which are sealed and in which the internal atmosphere may be purged by flushing with an inert gas fed in from a purger unit (30) via a suitable feed lead (35). The gas exhausted from inside the container (32) is fed back into the purge unit (30) and then checked against a desired parameter, for example oxygen concentration, until the value of that parameter reaches a desired level. Purging may then be stopped and the container left sealed, preferably at a slight over pressure relative to the ambient atmosphere. The use of a separate purge unit enables many containers to be sequentially and effectively processed. The containers are particularly useful for storing sensitive chemical and biological samples.
Abstract:
Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient, wherein expression of Epo is physiologically regulated such that hematocrit levels of the patient are corrected and maintained.